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Adiponectin Prevents Diabetic Premature Senescence of
Endothelial Progenitor Cells and Promotes Endothelial
Repair by Suppressing the p38 MAP Kinase/p16INK4A
Signaling Pathway
Junlei Chang,1,2 Yiming Li,3 Yu Huang,4 Karen S.L. Lam,1,2 Ruby L.C. Hoo,1,2 Wing Tak Wong,4
Kenneth K.Y. Cheng,1,2 Yiqun Wang,1,2 Paul M. Vanhoutte,2,5 and Aimin Xu1,2,5
OBJECTIVE—A reduced number of circulating endothelial pro-
genitor cells (EPCs) are casually associated with the cardiovas-
cular complication of diabetes. Adiponectin exerts multiple
protective effects against cardiovascular disease, independent of
its insulin-sensitizing activity. The objective of this study was to
investigate whether adiponectin plays a role in modulating the
bioavailability of circulating EPCs and endothelial repair.
RESEARCH DESIGN AND METHODS—Adiponectin knock-
out mice were crossed with db/ mice to produce db/db
diabetic mice without adiponectin. Circulating number of EPCs
were analyzed by flow cytometry. Reendothelialization was eval-
uated by staining with Evans blue after wire-induced carotid
injury.
RESULTS—In adiponectin knockout mice, the number of circu-
lating EPCs decreased in an age-dependent manner compared
with the wild-type controls, and this difference was reversed by
the chronic infusion of recombinant adiponectin. In db/db dia-
betic mice, the lack of adiponectin aggravated the hyperglyce-
mia-induced decrease in circulating EPCs and also diminished
the stimulatory effects of the PPAR agonist rosiglitazone on
EPC production and reendothelialization. In EPCs isolated from
both human peripheral blood and mouse bone marrow, treat-
ment with adiponectin prevented high glucose–induced prema-
ture senescence. At the molecular level, adiponectin decreased
high glucose–induced accumulation of intracellular reactive ox-
ygen species and consequently suppressed activation of p38 MAP
kinase (MAPK) and expression of the senescence marker
p16INK4A.
CONCLUSIONS—Adiponectin prevents EPC senescence by
inhibiting the ROS/p38 MAPK/p16INK4A signaling cascade. The
protective effects of adiponectin against diabetes vascular com-
plications are attributed in part to its ability to counteract
hyperglycemia-mediated decrease in the number of circulating
EPCs. Diabetes 59:2949–2959, 2010
Maintenance of an intact endothelial layeris essential for blood vessels to functionproperly and prevents the development ofvascular disease such as atherosclerosis.
Endothelial progenitor cells (EPCs), which were first
discovered in 1997 as circulating immature cells in periph-
eral blood of humans (1), are now recognized as an
important contributor to endothelial repair upon vascular
damage (2). EPCs express the markers of both hematopoi-
etic and endothelial lineages and reside mainly in the bone
marrow. In response to stimuli such as tissue ischemia,
EPCs can be mobilized into the bloodstream and then
home or migrate toward the area of vascular damage,
where they adhere, proliferate, and differentiate into ma-
ture endothelium, thereby leading to reendothelialization
and neovascularization.
The number of circulating EPCs is considered to be a
mirror of cardiovascular health. A reduced level of circu-
lating EPCs is a cellular marker that independently pre-
dicts the outcome of vascular disease (3). In both type 1
and type 2 diabetic patients, the circulating number of
EPCs is decreased compared with age- and sex-matched
healthy subjects (4). In addition to diabetes, other major
cardiovascular risk factors, including smoking, aging, hy-
pertension, and dyslipidemia, have been associated with
decreased number or dysfunction of circulating EPCs (5).
On the other hand, therapeutic interventions capable of
reducing cardiovascular risk factors, such as exercise,
treatment with glucose- or lipid-lowering drugs, augment
the number of EPCs and improve their functions in
endothelial repair (6,7).
Adiponectin is an important adipocyte-secreted adipo-
kine with insulin-sensitizing and antidiabetes properties
(8). Unlike most proinflammatory adipokines/cytokines
secreted by adipose tissue, the plasma concentrations of
adiponectin are decreased in obese individuals and pa-
tients with type 2 diabetes, hypertension, and cardiovas-
cular disease. Hypoadiponectinemia observed under these
pathogenic conditions is attributed primarily to insulin
resistance (9). On the other hand, the PPAR agonists
thiazolidinediones (TZDs) enhance adiponectin produc-
tion in both animals and humans (10).
In addition to its metabolic functions, adiponectin ex-
erts multiple protective effects against cardiovascular dis-
eases, including alleviation of stroke (11), myocardial
infarction (12), and diabetic cardiomyopathy (13). The
endothelium is a major target of adiponectin, where the
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adipokine promotes the production of nitric oxide (NO) by
endothelial NO synthase (eNOS), depletes intracellular
reactive oxygen species (ROS), and prevents inflammation
and activation, consequently improving endothelial func-
tion and delaying atherosclerosis (14,15). Emerging evi-
dence also demonstrates that adiponectin might be
involved in regulating the functions of EPCs (16,17). A
positive correlation between adiponectin and circulating
EPCs has been observed in a cross-sectional study on
Japanese (18). However, the precise roles of adiponectin
in regulating EPCs under various pathophysiological con-
ditions remain to be established.
The present study used adiponectin knockout (KO)
mice to investigate the impact of adiponectin deficiency on
the number of circulating EPCs during aging and under
obese/diabetic conditions. The in vivo results demonstrate
that lack of adiponectin aggravates the decrease in circu-
lating EPCs under both circumstances. The in vitro study
shows that adiponectin counteracts high glucose–induced
senescence of EPCs isolated from both human peripheral
blood and mouse bone marrow. Therefore, we further
examined the signaling pathways that mediate the actions
of adiponectin in both human and mouse EPCs.
RESEARCH DESIGN AND METHODS
Male adiponectin KO mice (19) with a C57BL/6J background and their
wild-type controls, leptin receptor/ (db/db) mice and leptin receptor//
adiponectin/ double knockout (DKO) mice (20) and their lean littermates
were used for this study. The mice were housed in a room under controlled
temperature (23  1°C) and 12-h light-dark cycles, with free access to water
and standard chow. All of the experiments were conducted under our
institutional guidelines for the humane treatment of laboratory animals.
Antibodies and recombinant proteins. Rabbit polyclonal antibody against
human p16INK4A and goat anti-mouse p16INK4A polyclonal antibody were
purchased from Santa Cruz Biotechnology. Rabbit anti–total p38 MAP kinase,
anti–phospho-p38 MAP kinase (Thr180/Tyr182), anti–total extracellular sig-
nal–regulated kinases 1 and 2 (ERK1/2), anti–phospho ERK1/2 (Thr 202/Tyr
204, cat no. 4370) antibodies were from Cell Signaling Technology. Phyco-
erythrin (PE)-conjugated monoclonal antibody against CD31, von Willebrand
factor (vWF), vascular endothelial growth factor (VEGF) receptor 2 (KDR),
and vascular endothelial (VE)-cadherin (CD144) were obtained from Beckman
Coulter. PE-conjugated anti-human CD14, fluoroisothiocyanate (FITC)-la-
beled anti-mouse fetal liver kinase (Flk)-1, and PE-conjugated anti-mouse
c-Kit were manufactured by BD Biosciences. Mouse full-length adiponectin
was expressed in HEK293 cells and purified from a serum-free conditioned
medium previously described (20). The endotoxin level was 0.1 EU/g
protein as determined by limulus amoebocyte lysate (LAL) chromogenic end
point assay (Hycutt Biotech).
Isolation and cultivation of human early EPCs from peripheral blood.
Human early EPCs were isolated from healthy volunteers aged from 21 to 35
years as previously described (21). In brief, mononuclear cells were isolated
from peripheral blood by Ficoll density gradient centrifugation and cultured
on fibronectin-coated dishes in Medium 199 supplemented with 20% FBS and
VEGF. Four days after the growth, nonadherent cells were removed and were
grown for another 3 days. The immunophenotypic characterization was
conducted by fluorescence-activated cell sorter (FACS) analysis using the
antibodies against a panel of endothelial and monocytic markers, including
KDR, VE-cadherin, vWF, and CD14.
Quantification of circulating EPC number by flow cytometry. Total
mononuclear cells were isolated from mouse peripheral blood as described
above. After washing twice with Dulbecco’s phosphate-buffered saline (DPBS)
plus 2 mmol/l EDTA, cells were resuspended in DPBS/1% FBS/0.1% NaN3 and
were then double stained with PE-conjugated anti-mouse c-Kit and FITC-
conjugated anti-Flk-1 monoclonal antibodies or PE-conjugated rat anti-mouse
CD31 and FITC-conjugated rat anti-mouse CXCR4 monoclonal antibodies at
4°C for 1 h in dark. Isotype-identical antibodies were used as negative
controls. After staining, cells were washed twice with PBS and resuspended in
DPBS/1% FBS/0.1% NaN3 for analysis on the flow cytometer (FC 500 with CXP
software; Beckman Coulter). Cell viability was determined by staining with
7-AAD (Invitrogen). 50,000 viable cells were analyzed in each sample. Circu-
lating EPCs and circulating angiogenic cells were defined as cells coexpress-
ing c-Kit and Flk-1 or CD31 and CXCR4, respectively (22).
Surgical procedures for wire-induced carotid denudation. Mice were
anesthetized, and the bifurcation of the right carotid artery was exposed via
midline incision of the ventral side of the neck under a dissection microscope.
Two ligatures were placed proximally and distally around the external carotid
artery. After temporary occlusion of the internal, common, and external
carotid artery, a transverse arteriotomy was performed on internal carotid
artery and an angioplasty wire (0.39 mm) was introduced between the
ligatures of the external carotid artery up to 4 mm from the bifurcation. The
wire was passed along the common carotid artery four times under rotation.
After removal of the wire, the proximal ligature was tied off proximal and
distal to the incision hole of the external carotid artery. Normal blood flow
was restored, and the skin was closed with single sutures using 5/0 silk. Mice
were recovered on heated pads for the first 8 hours.
Reendothelialization assay. Four days after carotid injury, mice were
infused with 60 l of 5% Evans blue dissolved in saline via tail vein injection.
Ten minutes after injection, mice were killed with an overdose of Hypnorm
and Dormicum. The anesthetized mice were then perfused with saline to wash
out whole blood and the excess dye and the stain was fixed via perfusion with
4% paraformaldehyde. Ten minutes after fixation, carotid arteries were
dissected out and opened longitudinally for en face histological assessments.
Regions of damaged endothelium incorporate the stain and appear blue,
whereas areas with reendothelialization are resistant to the dye. Both stained
and unstained areas were outlined and quantified with the NIH Image J
software.
Isolation and cultivation of bone marrow–derived EPCs from mice.
Linc-KitFlk-1 bone marrow cells were isolated using the magnetic sorting
method as described in the supplemental data, available in an online appendix
(http://diabetes.diabetesjournals.org/cgi/content/full/db10-0582/DC1). The iso-
lated cells were seeded (2  105 cells/well) on 8-well glass chamber slides
precoated with 20 g/ml fibronectin (Sigma-Aldrich) in M199 medium supple-
mented with 20% FBS. Over 90% of the Linc-KitFlk-1 cells expressed
CD31, c-kit and Flk-1 and were positively stained for Dil-ac-LDL (molecular
probes) and FITC-labeled lectin (sigma). These bone marrow–derived EPCs
were used for further functional characterization.
Isolation of bone marrow–derived EPCs from mice using a magnetic
cell sorting method. Total mononuclear cells were isolated from mouse
bone marrow using Histopaque-1083 (Sigma) density gradient centrifugation,
and mature hepatopoietic cells were depleted using Mouse Lineage Cell
Depletion Kit (Miltenyi Biotec) according to the manufacturer’s instruction.
The lineage negative cells were subjected to separation using CD117 (c-Kit)
microbeads. The resulting Linc-Kit cells were stained with FITC-conjugated
primary antibody against Flk-1, followed by magnetic labeling with an
anti-FITC MultiSort kit and separation using a mini-MACS column.
Quantification of the EPCs number in peripheral blood by culture
assay. Total mononuclear cells were isolated from 800 l peripheral blood of
mice using Histopaque-1083 (Sigma) density gradient centrifugation and
cultured in endothelial growth medium-2 (Clonetics) medium including anti-
biotics, growth factors, and 10% FBS. To determine the number of EPCs, cells
were grown on 4-well glass chamber slides coated with rat plasma vitronectin
(Sigma) in 0.5% gelatin (Sigma). After 4 days of culture, nonadherent cells
were removed by washing with DPBS (Sigma) thoroughly and attached EPCs
were characterized by DiI-acLDL (Invitrogen) and FITC–Bandeiraea simplici-
folia–1 lectin (Sigma) double staining. Double-positive cells were counted in
ten randomly selected high-power fields of each cultured slide under a
fluorescent microscope (100).
Quantification of p16INK4A mRNA expression by quantitative PCR
analysis. Total RNA was isolated from human early EPCs using TRIzol
reagent (Invitrogen) and treated with RNase-free DNase (Promega, Madison,
WI) at 37°C for 30 min to remove genomic DNA. For reverse transcription, 1
g total RNA was converted into first-strand complementary DNA in 20-l
reactions using the ImProm-II Reverse Transcriptase kit (Promega). The
mRNA abundance of p16INK4A was determined by quantitative real-time PCR
in duplicate in a total reaction volume of 20 l with SYBR Green PCR Master
Mix on an ABI Prism 7000 instrument (Applied Biosystems), using the
following primers: 5-GAC CTG GCT GAG GAG CTG-3 (forward) and 5-TTC
AAT CGG GGA TGT CTG A-3 (reverse). The PCR conditions were set as
follows: 50°C for 2 min and 95°C for 10 min, followed by 35 two-step cycles at
95°C for 15 s and 60°C for 1 min. 	-actin (forward primer, 5 TGA CCC AGA
TCA TGT TTG AGA 3, and reverse primer, 5AGT CCA TCA CGA TGC CAG
T 3) was amplified at the same plate for each sample for normalization
purpose. Analysis was performed with ABI Prism 7000 SDS software.
Measurement of intracellular cAMP levels. The effects of adiponectin on
intracellular cAMP levels in human early EPCs were measured with the cAMP
Biotrak Enzymeimmunoassay system using the protocol recommended by the
manufacturer (GE Healthcare). In brief, cells grown in 24-well dishes for 48 h
were dissolved with the lysis reagents provided in the kit to release intracel-
lular cAMP. The cell lysates were transferred immediately into a 96-well
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microplate precoated with rabbit anti cAMP for the subsequent assay. The
protein concentration was determined by a bicinchoninic acid assay (Pierce).
The intracellular cAMP concentration was expressed as picomoles per
microgram of cellular protein.
Quantification of angiogenic growth factors secreted from human early
EPCs. Four days after isolation of early EPCs, cells were grown in a growth
factor–free basal M199 medium supplemented with 5% FCS for 48 h. Condi-
tioned media were analyzed to determine the concentrations of VEGF,
granulocyte-macrophage colony stimulating factor, and hepatocyte growth
factor using the immunoassay kits from R&D systems.
Measurement of intracellular ROS. The fluorescent probe 5-(and-6)-chlo-
romethyl-2,7-dichlorodihy-drofluorescein diacetate (CM-H2DCFDA) was
used to determine the intracellular generation of ROS in human EPCs. EPCs
in 24-well plates were grown in 5 or 25 mmol/l glucose for 72 h under various
treatments. Thereafter, the cells were incubated with 5 mol/l CM-H2DCF-DA
for 30 min at 37°C. After removal of the media and washing of the cells, the
fluorescence intensity (relative fluorescence units) was measured at an
excitation and emission wavelength of 485 nm and 530 nm, respectively, using
a spectrofluorometer (Hitachi).
Senescence-associated -galactosidase activity assay. Human early
EPCs or mouse bone marrow–derived EPCs were isolated and cultured as
described above. The cells were incubated with recombinant adiponectin or
25 mmol/l glucose for 72 h. The cellular senescence was detected using a
Senescent Cells Staining Kit (Sigma). Blue-stained cells and total cells were
counted respectively and the percentage of 	-galactosidase–positive cells was
calculated.
Western blot analysis. Cellular proteins from EPCs under various treat-
ments were resolved by SDS-PAGE and probed with different primary and
secondary antibodies as specified in the figure legends. The proteins were
visualized by the chemiluminescence detection. The relative band densities
were quantified using the MultiAnalyst software package (Bio-Rad).
Statistical analysis. Data are expressed as means  SD. Statistical signifi-
cance was determined by one-way ANOVA or Student’s t test. P values 0.05
were accepted as indicatative of statistically significant differences.
RESULTS
Circulating numbers of EPCs are modulated by adi-
ponectin in mice. Flow cytometry analysis showed that
the number of circulating c-KitFlk-1 EPCs in adiponec-
tin KO mice progressively decreased in an age-dependent
manner (Fig. 1A and B). At 28 weeks old, adiponectin KO
mice had a circulating number of EPCs 
50% lower than
that in wild-type controls. A similar result was also ob-
served when the EPC number was determined by the
culture assay (Fig. 1C). On the other hand, there was no
obvious difference in the number of total circulating
mononuclear cells between the two groups (Fig. 1D).
We next investigated the effects of adiponectin supple-
mentation on the number of circulating c-KitFlk-1 EPCs
in mice. To this end, recombinant adiponectin produced
from mammalian cells was delivered into both adiponectin
KO mice and wild-type littermates using Alzet osmotic
pumps as previously described (23). Serum levels of
adiponectin started to increase at the second day of the
treatment in both types of mice (supplemental Fig. 1A in
the online appendix). Noticeably, the increase in serum
adiponectin was accompanied by significant elevation of
the number of circulating EPCs in both wild-type and
adiponectin KO mice (supplemental Fig. 1B).
Rosiglitzone-mediated increase in circulating EPCs
and improvement in reendothelialization are depen-
dent on adiponectin. To further explore the role of
adiponectin in modulating the circulating number of EPCs
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FIG. 1. Circulating EPCs are progressively decreased in adiponectin KO mice. A: Representative FACS analysis of circulating EPCs from
25-week-old adiponectin KO and wild-type (WT) controls double stained for c-Kit (x-axis) and Flk-1 (y-axis). B: Comparison of the percentage
of c-Kit/Flk-1 double-positive EPCs in peripheral blood between adiponectin KO mice and wild-type controls at different ages (in weeks). Data
are expressed as % of total mononuclear cells in blood. C: Quantification of circulating EPCs by culture assay. D: Quantification of total
mononuclear cells in adiponectin KO mice and wild-type controls via a hemocytometer. **P < 0.01 vs. wild-type controls (n  5–7).
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under the pathological conditions, adiponectin KO mice
were crossed with db/ mice (a genetically inherited
obese/diabetic mouse model due to the lack of functional
leptin receptors) to generate db//adiponectin/ DKO
mice (20). As expected, db/ mice displayed typical
diabetic phenotypes, including hyperglycemia, hyperinsu-
linemia, and dyslipidemia (supplemental table 1). Com-
pared with the lean controls, the number of circulating
EPCs in db/ mice was significantly reduced at both
baseline and 4 days after carotid injury (Fig. 2A). Notice-
ably, the number of circulating EPCs in DKO mice were
further decreased by 50.2% at baseline and 61.4% at 4 days
after carotid injury, respectively, compared with db/
obese/diabetic mice, despite the fact that DKO mice and
db/ mice had comparable blood levels of glucose, insu-
lin, and body weight gains.
Administration of the PPAR agonist rosiglitazone (20
mg  kg1 body wt  day1) to db/ obese/diabetic mice
for a period of 4 weeks increased serum levels of adi-
ponectin by approximately twofold. This change in serum
adiponectin was accompanied by a significant elevation in
the number of circulating EPCs at both baseline and 4 days
after carotid injury (Fig. 2A). On the other hand, the
magnitude of rosiglitazone-mediated increase in circulat-
ing EPCs in DKO mice was significantly smaller than that
observed in db/ mice (1.64  0.22 vs. 2.53  0.31 fold;
P  0.01; n  6), although the effects of this drug on
decreasing hyperglycemia and hyperinsulinemia were
comparable between db/ mice and DKO mice (supple-
mental table 1).
In line with the changes in the number of circulating
EPCs, db/ mice exhibited an impaired reendothelializa-
tion compared with their lean littermates, and this impair-
ment was further aggravated in DKO mice (Fig. 2B and C).
Treatment with rosiglitazone completely reversed the im-
pairment in reendothalization in db/ mice, whereas this
effect of rosiglitazone was largely abolished in DKO mice.
Adiponectin counteracts hyperglycemia-induced in-
duction of cellular senescence. To further study the
underlying mechanism whereby adiponectin increases cir-
culating EPCs, we evaluated the direct effect of recombi-
nant adiponectin on human EPCs isolated from peripheral
blood of healthy subjects. The cells exhibited a typical
spindle-shaped, endothelial cell–like morphology (Fig.
3A). Over 90% of adherent cells were double positive for
uptake of acetylated LDL and binding to lectin Ulex
europaeus agglutinin-1 (UEA-1), a characteristic feature of
EPCs. Further FACS analysis showed that 75% of adher-
ent cells expressed endothelial cell–specific markers, in-
cluding KDR (81.3  5.6%), vWF (84.1  6.7%), and
VE-cadherin (76.2  7.9%) (Fig. 3B). In addition, positive
immunostaining for the monocytic marker CD14 was
identified in 89.6  3.2% of the cells. However, these cells
did not proliferate (as determined by both BrdU incorpo-
ration assay and direct cell counting) and did not have the
capacity for tube formation (data not shown). Consistent
with previous findings (24,25), the cells secreted high
levels of several angiogenic growth factors, including
VEGF, granulocyte-macrophage colony stimulating factor
granulocyte-macrophage colony stimulating factor, and
hepatocyte growth factor (Fig. 3C). Taken together, these
cells showed the characteristic features of early EPCs
(24), which are also defined as circulating monocyte–
related angiogenic cells (25), or endothelial cell colony–
forming units (26).
Exposure of human early EPCs to high glucose (25
mmol/l) for 72 h had no obvious effect on apoptosis (data
not shown) but led to a marked induction of cellular
senescence, as determined by staining for senescence-
associated 	-galactosidase (Fig. 4A and B). Treatment of
cells with recombinant adiponectin reversed high glucose–
induced cellular senescence in a dose-dependent manner.
However, adiponectin had no obvious effect on senes-
cence when human early EPCs were cultured in the
presence of a normal glucose concentration.
Adiponectin suppresses hyperglycemia-induced acti-
vation of p38 MAP kinase and expression of p16INK4A
in human early EPCs. p38 MAP kinase (MAPK) plays a
key role in downregulating EPCs by hyperglycemia in
diabetic patients (27). This kinase has been shown to
inhibit EPCs proliferation and to promote EPCs senes-
cence through inducing the expression of the senescence-
associated cyclin-dependent kinase inhibitor p16INK4A
(28,29). We next tested the effect of adiponectin on the p38
MAPK/p16INK4A pathway in human EPCs. Incubation of
EPCs with high glucose significantly increased the phos-
phorylation of both p38 MAPK and ERK1/2 and also
caused a significant elevation of p16INK4A mRNA expres-
sion compared with control cells (Fig. 5A–C). The expres-
sion of p16INK4A protein was barely detectable when
cultured under normal glucose conditions but was mark-
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FIG. 2. An indispensible role of adiponectin in rosiglitazone (Rosi)-
induced increase in circulating EPCs and reendothelialization in db/
mice. Eight-week-old male db/ mice or DKO mice were treated with
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operation. *P < 0.05; **P < 0.01 (n  5–6 in each group). (A
high-quality digital representation of this figure is available in the
online issue.)
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edly induced following prolonged exposure to high glu-
cose (Fig. 5D). Treatment of human early EPCs with
adiponectin significantly reduced high glucose–induced
increase in phosphorylation of both p38 MAPK and
ERK1/2 and prevented the high glucose–induced mRNA
and protein expression of p16INK4A but did not affect those
parameters significantly under normal glucose conditions.
Incubation of cells with the p38 MAPK selective inhibi-
tor SB203508, but not the ERK1/2 MAPK selective inhibitor
PD98059, abrogated high glucose–induced expression of
p16INK4A as well as cellular senescence (supplemental Fig.
2). The combined treatment of cells with SB203508 and
adiponectin did not result in additive effects on the inhi-
bition of high glucose–induced p16INK4A expression and
cellular senescence. Adiponectin treatment also sup-
pressed high glucose–induced phosphorylation of c-Jun
NH2-terminal kinases (JNKs). However, incubation of cells
with the synthetic inhibitor of JNK (SP600125) had no
effect on high glucose–induced p16INK4A expression or
senescence of EPCs (data not shown).
Adiponectin decreases high glucose–induced ROS ac-
cumulation in EPCs through a mechanism dependent
on both AMP-activated protein kinase and cAMP.
Intracellular accumulation of ROS is a major risk factor for
inducing premature senescence of hematopoietic stem
cells through activation of p38 MAPK pathway (30). Hy-
perglycemia can increase ROS production in many cell
lines, including EPCs (21). We next investigated whether
adiponectin counteracts high glucose–induced cellular se-
nescence through suppressing ROS production. Chronic
exposure of EPCs to high glucose significantly increased
intracellular dichlorofluorescein (DCF)-sensitive ROS lev-
els compared with cells grown in normal glucose or in
osmotic control medium (Fig. 6). Treatment of the cells
with recombinant adiponectin reversed the effects of
hyperglycemia on intracellular ROS accumulation in a
dose-dependent manner. The suppressive effect of adi-
ponectin on high glucose–induced ROS accumulation was
partially attenuated by treatment with compound C (a
selective inhibitor of AMP-activated protein kinase) or by
H-89 (a cell-permeable inhibitor of protein kinase A) and
was abolished by combination of the two pharmacological
inhibitors. Noticeably, compound C exerted a much
greater inhibitory effect than H-89 on adiponectin-induced
decrease in intracellular ROS accumulation.
In line with the changes in intracellular ROS accumula-
tion, the inhibitory effects of adiponectin on high glucose–
induced phosphorylation of p38 MAPK was reduced by
either compound C or H-89 and was abrogated by com-
bined treatment with the two inhibitors (Fig. 7A). When
the cells were treated with compound C and H-89 alone,
the inhibitory effect of adiponectin on high glucose–
induced phosphorylation of p38 MAPK was attenuated by

57 and 26%, respectively. Incubation of human early
EPCs with compound C, but not with H-89, significantly
attenuated the suppressive effects of adiponectin on high
glucose–induced p16INK4A expression and cellular senes-
cence (Fig. 7B and C). Furthermore, combined treatment
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with compound C plus H-89 did not cause further attenu-
ation in adiponectin-mediated suppression of p16INK4A
expression or cellular senescence when compared with
that treated with compound C alone.
Real-time PCR analysis showed that amp-activated pro-
tein kinase (AMPK) 1, but not AMPK 2, was the pre-
dominant isoform expressed in human early EPCs (data
not shown). The inhibitory effect of adiponectin on high
glucose–induced ROS production was reduced by
51 and
24% by knocking down of AMPK 1 and the catalytic
subunit of protein kinase A (PKA)- respectively, and by

68% by simultaneous knockdown of these two kinases
(supplemental Fig. 3). Knockdown of AMPK 1 signifi-
cantly attenuated adiponectin-mediated suppression of
high glucose–induced cellular senescence of EPCs,
whereas knockdown of PKA alone had little effect.
Treatment of cells with the antioxidant N-acetylcysteine
(a thiol-containing radical scavenger) prevented high glu-
cose–induced phosphorylation of p38 MAPK, p16INK4A
expression, and cellular senescence (Fig. 7A–C).
Adiponectin suppresses hyperglycemia-induced
p16INK4A expression and senescence of EPCs by de-
creasing ROS accumulation in diabetic mice. Consis-
tent with the findings in human early EPCs, mouse EPCs
isolated from bone marrow of db/ diabetic mice
exhibited a significant elevation in intracellular ROS
accumulation, p38 phosphorylation, and p16INK4A ex-
pression compared with those from the lean littermates
(Fig. 8A–C), and these changes were completely re-
versed by treatment of db/ diabetic mice with rosigli-
tazone for a period of 4 weeks. The intracellular ROS
accumulation, p38 phosphorylation, and p16INK4A ex-
pression in bone marrow–derived EPCs from DKO mice
were significantly higher than those from db/ mice.
Furthermore, the ability of rosiglitazone to reverse
these diabetes-induced changes were significantly com-
promised, suggesting that rosiglitazone-mediated inhibi-
tion of ROS production, p38 phosphorylation, and
p16INK4A expression is mediated at least in part by
adiponectin. Bone marrow EPCs isolated from DKO
mice were more susceptible to high glucose–induced
senescence compared with those from db/ mice (Fig.
8D and E). On the other hand, recombinant adiponectin
was able to inhibit high glucose–induced senescence
of EPCs isolated from DKO mice to a level comparable
with that observed in db/ mice, indicating that EPCs
originated from DKO mice are hypersensitive to
adiponectin.
In DKO mice, the expression of p16INK4A in bone mar-
row–derived EPCs was elevated by 2.6 folds from the age
of 8–12 weeks, and this change was accompanied by
52%
decline in circulating EPCs (supplemental Fig. 4). Treat-
ment of DKO mice with either the antioxidant NAC or
recombinant adiponectin for 4 weeks prevented the aging-
associated elevation of p16INK4A expression and stopped
the decline in circulating EPCs in DKO mice.
DISCUSSION
The present study demonstrates that adiponectin protects
against both aging- and diabetes-induced decrease in cir-
culating EPCs in mice. This finding corroborates a recent
clinical observation showing a positive association be-
tween the plasma levels of adiponectin and the number of
EPCs in patients with coronary heart disease (18), suggest-
ing that the vasculoprotective effects of adiponectin are
attributed in part to its ability to increase the availability of
circulating EPCs.
Another novel observation of this study is that the
beneficial effect of the PPAR agonist rosiglitazone (a
thiazolidinedione class of antidiabetic drug) in elevating
the number of circulating EPCs is diminished in db/db
diabetic mice without adiponectin. In addition to their
well-established efficacy in improving insulin sensitivity
and glycemic control, thiazolidinediones have potent
protective effects against the vascular complications of
diabetes by reducing both classical and nonclassical
risk factors for cardiovascular disease (31). A growing
body of evidence shows that treatment with rosiglita-
zone or pioglitazone increases the circulating number of
EPCs and normalizes their impaired endothelial repair
capacity in patients with type 2 diabetes or coronary
heart disease (6,7,21). Noticeably, the elevation of cir-
culating EPCs by the PPAR agonists is accompanied by
an increased plasma level of adiponectin in these pa-
tients. The PPAR agonists have been shown to induce
adiponectin production in adipocytes through transcrip-
tional activation as well as by enhancing its secretion
(32). Taken in conjunction, these findings suggest that
the beneficial effects of PPAR agonists in increasing
the number and improving the functions of circulating
EPCs are mediated in part by their ability to induce
adiponectin production from adipocytes.
** 
NG HG HG + ADN (15 µg/mL) 
A 
0 
0.2 
0.4 
0.6 
0.8 
1.0 
1.2 
1.4 
1.6 
1.8 
Se
ne
sc
en
t E
PC
s (
fo
ld
 o
f c
on
tro
l) 
  0          0           0           5          10         15 
ADN (µg/mL) 
# 
## 
B 
FIG. 4. Adiponectin prevents high glucose–induced cellular senescence
of human EPCs. Cells isolated as in Fig. 3 were grown in normal glucose
(NG) (open bar), normal glucose plus 20 mmol/l mannitol as an osmotic
control (gray bar), or high glucose (HG) (black bar) in the absence or
presence of different concentrations of recombinant adiponectin
(ADN) for 72 h. EPC senescence was evaluated by senescence-associ-
ated -galactosidase staining. A: Representative photographs of senes-
cence-associated -galactosidase–stained blue EPCs under normal
glucose, high glucose, and high glucose plus 15 g/ml adiponectin. B:
The degree of cell senescence was quantified as the percentage of
senescence-associated -galactosidase–positive cells and expressed as
fold of normal glucose control. **P < 0.01 vs. normal-glucose group.
#P < 0.05, ##P < 0.01 vs. the high-glucose group without adiponectin
treatment (n  5–6). (A high-quality digital representation of this
figure is available in the online issue.)
PROTECTION AGAINST EPC SENESCENCE BY ADIPONECTIN
2954 DIABETES, VOL. 59, NOVEMBER 2010 diabetes.diabetesjournals.org
Hyperglycemia is a primary contributor to the re-
duced number and impaired functions of EPCs in dia-
betes (33). In humans, the number of circulating EPCs
correlates inversely with the fasting blood glucose
concentration as well as the A1C level (4,34). In vitro
studies demonstrate that high glucose decreases the
EPC number by reducing cell proliferation (35), increas-
ing apoptosis (36), and accelerating premature senes-
cence (37–39). However, it is noteworthy that high
glucose–induced apoptosis of EPCs was observed only
when the cells were cultured in the presence of 50
mmol/l glucose (36). In the present study, we found that
prolonged exposure of human EPCs to 25 mmol/l glu-
cose for 3 days does not induce obvious apoptosis but
leads to a marked elevation of premature senescence, as
determined by senescence-associated 	-galactosidase
assay. These results are in line with several recent
reports that high glucose ranging from 10 to 25 mmol/l
reduces the self-renewal capacity and induces senes-
cence of human EPCs but not their apoptosis (27,39).
Furthermore, stress-induced premature senescence, but
not apoptosis, is attributed to tumor necrosis factor-–
induced decrease in the number of human EPCs (28).
The present results demonstrate that adiponectin
prevents high glucose–induced EPC senescence by
downregulating the expression of p16INK4A, a well-estab-
lished senescent marker that has recently been shown
to be a key mediator of the aging process in stem cells
(29). In hematopoietic stem cells, ROS induces the
expression of p16INK4A through activation of p38 MAPK,
and this in turn limits the lifespan of the cells by
inducing senescence (30). Hyperactivation of the ROS/
p38 MAPK pathway appears to be a primary contributor
to the reduced number and dysfunction of EPCs in
diabetic patients and elderly individuals (21,27). EPCs
from diabetic patients contain a substantially higher
ROS level compared with those of healthy individuals,
and suppression of high glucose–induced ROS accumu-
lation by either pharmacological or genetic intervention
reverses the reduced number and the impaired reendo-
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thelialization capacity of EPCs associated with diabetes
(21,40). Likewise, pharmacological inhibition of p38
MAPK alone is sufficient to increase the number of EPCs
in patients with cardiovascular disease and to prevent
premature EPC senescence induced by high glucose or
TNF- (27,28,37). Consistent with these findings, the
present results show that high glucose–induced
p16INK4A expression and senescence of EPCs is largely
mitigated by either the antioxidants (N-acetylcysteine
[NAC]) or by the p38 MAPK selective inhibitor SB203508
but not by the ERK1/2 inhibitor PD98059 or the JNK
inhibitor SP600125. Furthermore, the inhibition of high
glucose–induced premature senescence by adiponectin
is accompanied by a marked reduction in intracellular
accumulation of ROS and activation of p38 MAPK. It is
noteworthy that the suppression of p38 MAPK by adi-
ponectin was observed only when it was activated by
high glucose and not under normal glucose conditions,
suggesting that the effect of adiponectin on p38 MAPK is
indirect, perhaps secondary, to the decrease of intracel-
lular ROS.
The antioxidant property of adiponectin has been impli-
cated previously in both clinical and animal studies
(15,20,41,42). In humans, plasma levels of adiponectin
correlate inversely with the markers of oxidative stress
(such as 8-epi-prostaglandin F2) (41). Adiponectin has
been shown to decrease oxidative stress in cardiomyo-
cytes (42), mature endothelial cells (15), and liver cells
(20,43), although the underlying mechanism is still a
matter of debate. In human umbilical vein endothelial
cells, the suppressive effect of adiponectin on high glu-
cose–induced ROS production is mediated predominantly
by the cAMP/PKA pathway but not AMPK (15). On the
other hand, the antioxidant activity of adiponectin in
hepatocytes and hepatic stellate cells is primarily a down-
stream event of AMPK activation, which in turn induces
expression of uncoupling protein-2 that inhibits mitochon-
dria ROS production (20,44). In this study, we showed that
both cAMP/PKA and AMPK potentially contribute to adi-
ponectin-mediated suppression of high glucose–evoked
ROS production in human EPCs. This conclusion is sup-
ported by the fact that a complete abrogation in the
antioxidant activity of adiponectin was achieved only
when both PKA and AMPK were inhibited. Noticeably,
pharmacological or genetic inhibition of PKA had little
effect on adiponectin-induced suppression of high glu-
cose–induced p16INK4A expression and senescence of
EPCs. This finding suggests that cAMP/PKA only plays a
minor role in mediating the suppressive effect of adiponec-
tin on high glucose–induced ROS production and senes-
cence of EPCs. On the other hand, pharmacological or
genetic inhibition of AMPK alone was sufficient to attenu-
ate the suppressive effect of adiponectin on high glucose–
induced ROS accumulation, p38 MAPK, or senescence of
EPCs, suggesting that AMPK is likely to be an key media-
tor of adiponectin actions in EPCs.
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In line with our findings, a number of recent studies
have documented the suppressive effect of AMPK on high
glucose–induced oxidative stress in endothelial cells by
promoting mitochondrial biogenesis (45) and inhibiting
NADPH oxidase activity (46) or by inducing the expres-
sion of uncoupling protein-2 (20,44). Although the role of
AMPK in EPCs remains poorly understood, pharmacolog-
ical activation of this kinase promotes adhesion and
differentiation of EPCs in vitro (47). Therefore, besides
protection against premature senescence, AMPK activa-
tion by adiponectin might exert additional benefits on
enhancing the reendothelialization capacity of EPCs in vivo.
In summary, the present study provides both in vivo and
in vitro evidence supporting the protective effects of
adiponectin against diabetes-induced decrease in the num-
ber of EPCs and impairment in endothelial repair. These
findings suggest that pharmacological intervention to in-
crease the production of adiponectin by adipocytes and/or
to enhance adiponectin signaling pathways might repre-
sent an effective therapeutic strategy to improve endothe-
lial repair and neovascularization in patients with diabetes
and cardiovascular disease. However, the findings in this
study were mainly based on rodent models and in vitro
experiments. The clinical relevance of these findings re-
mains to be established. Because both subtypes of adi-
ponectin receptors (adipoR1 and adipoR2) are expressed
in human early EPCs and mouse bone marrow–derived
EPCs, whether the favorable effects of adiponectin in
these cells are mediated by these two receptors requires
further investigation.
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